50mg semaglutide Day 5: Rybelsus (Oral Semaglutide) Class: GLP-1 receptor agonist Avg Weight Loss: 5–10% FDA Approved: 2019 for T2DM; being studied for obesity Pros: First oral GLP-1 agonist Non-injection option Effective Is 50 units of semaglutide

Promotes actin polymerization, cell migration, and structural protein expression, aiding softtissue repair, angiogenesis, and reduced fibrosis

R.BennettE

As of January 5, 2026, there are 3,063 active lawsuits against Novo Nordisk and other GLP-1 drug manufacturers, according to court documents

Feng Z-T, Xu J, He G-C, Cai S-J, Li J, Mei Z-G

Serious side effects Common (may affect up to 1 in 10 people) complications of diabetic eye disease (retinopathy) you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine

and The beneficiary meets one of the following criteria at the start of GLP-1 therapy: BMI greater than or equal to 35